DS-1103 is under clinical development by Integral Molecular and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DS-1103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DS-1103 overview
DS-1103 is under development for the treatment of solid tumor, HER2 positive breast cancer, gastric cancer, gastroesophageal junction carcinoma and non-small cell lung cancer. The drug candidate is developed based on membrane proteins (MPS) discovery platform. It is administered through intravenous route. It acts by targeting SIRPa.
Integral Molecular overview
Integral Molecular is a pharmaceutical company. The company’s pipeline products include CLDN6 is for the treatment of ovarian, endometrial; CLDN18.2 treats gastric, pancreatic, solid tumors; GPRC5D targeting multiple myeloma; CCR8 treats immuno oncology. It utilizes MPS antibody discovery platform to discover monoclonal antibodies and delivering lead molecules against difficult targets. Membrane Proteome Array is a technology platform is a cell-based array that contains set of human membrane proteins assembled to determine specificity and preclinical safety of antibodies, CAR-T cell therapies. Integral Molecular is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of DS-1103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
